Key Record Dates
| ClinicalTrials.gov Identifier: | NCT02089685 |
|---|---|
| Brief Title: | Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) |
| First Submitted : | March 14, 2014 |
| First Submitted that Met QC Criteria : | March 14, 2014 |
| First Posted : | March 18, 2014 (Estimate) |
| Results First Submitted : | March 22, 2022 |
| Results First Submitted that Met QC Criteria : | April 25, 2022 |
| Results First Posted : | May 18, 2022 |
| Last Update Submitted that Met QC Criteria : | August 22, 2022 |
| Last Update Posted : | September 13, 2022 |